TD Cowen: 'AstraZeneca's (AZN) history of innovation offers opportunity for upside'
Tweet Send to a Friend
(Updated - March 18, 2026 9:26 AM EDT)
TD Cowen analyst Steve Scala reiterated a Buy rating and $240.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
TD Cowen analyst Steve Scala reiterated a Buy rating and $240.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
